pT3-EF1aH Citations (4)

Originally described in: TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
Wang H, Zhang S, Zhang Y, Jia J, Wang J, Liu X, Zhang J, Song X, Ribback S, Cigliano A, Evert M, Liang B, Wu H, Calvisi DF, Zeng Y, Chen X J Hepatol. 2021 Aug 28. pii: S0168-8278(21)02016-X. doi: 10.1016/j.jhep.2021.08.021. PubMed Journal

---

Articles Citing pT3-EF1aH

Articles
Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression. Wu G, Wang Q, Wang D, Xiong F, Liu W, Chen J, Wang B, Huang W, Wang X, Chen Y. Clin Transl Med. 2023 Dec;13(12):e1502. doi: 10.1002/ctm2.1502. PubMed
METTL3-Mediated m6A Modification Regulates the Polycomb Repressive Complex 1 Components BMI1 and RNF2 in Hepatocellular Carcinoma Cells. Chen W, Zhang J, Ma W, Liu N, Wu T. Mol Cancer Res. 2025 Mar 3;23(3):190-201. doi: 10.1158/1541-7786.MCR-24-0362. PubMed
Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma. Zhu J, Xiong Y, Zhang Y, Liang H, Cheng K, Lu Y, Cai G, Wu Y, Fan Y, Chen X, Zhu H, Ding Z, Zhang W. Cancer Commun (Lond). 2025 Aug;45(8):1038-1071. doi: 10.1002/cac2.70036. Epub 2025 May 29. PubMed
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma. Cui G, Zhou Y, Liao W, Cossu E, Evert M, Zhang S, Wang J, Deng S, Yonemura A, David L, Xu M, Doumergue JM, Lu X, Yang L, Li J, Liang B, Wang H, Xu H, Zhong S, Deng Y, Calvisi DF, Zhao J, Chen X, Wang X. Cancer Res. 2025 Dec 15;85(24):5049-5065. doi: 10.1158/0008-5472.CAN-25-1615. PubMed

If you have published an article using this material, please email us at to have your article added to this page.